Abstract
Abstract H1 Patents – European Patents – Pharmaceuticals – Tadalafil – Dosing regimens – Revocation – Obviousness – Obvious to try – Fair expectation of success – Relevant factors – Dose ranging studies – Routine tests – Whether permissible to take into account information not available at priority date – The “patent bargain” – The “problem-and-solution” approach – Role of the appellate court – Appeal to Supreme Court
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
